Establishing a robust radioligand therapy program: A practical approach for North American centers
Cancer Medicine · 2024
DOI: 10.1002/cam4.6780 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2024. Verfasst von Erik S Mittra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including gastroenteropancreatic neuroendocrine tumors, lymphoma, and most recently, advanced prostate cancer. In the United States, patient access to this therapy is currently variable. Implementation of new RLT programs and expansion of existing programs are needed to broaden patient access to and standardize the delivery of RLT, especially as new therapies are introduced into clinical practice. Drawing from experience in establishing RLT programs in different settings, we have developed practical recommendations for building and implementing a robust RLT program. In this review, we present our recommendations for minimal requirements and optimal requirements, as well as system considerations, and special issues associated with implementing an RLT program in North American centers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Oregon Health & Science University, Portland, Oregon, USA.
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
- Department of Nuclear Medicine, West Tennessee Healthcare, Jackson, Tennessee, USA.
- Providence Cancer Institute, Portland, Oregon, USA.
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Mittra, E. S., Wong, R. K. S., Winters, C., Brown, A., Murley, S., & Kennecke, H. (2024). Establishing a robust radioligand therapy program: A practical approach for North American centers. Cancer Medicine. https://doi.org/10.1002/cam4.6780
Vancouver
Mittra ES, Wong RKS, Winters C, Brown A, Murley S, Kennecke H. Establishing a robust radioligand therapy program: A practical approach for North American centers. Cancer Medicine. 2024. doi:10.1002/cam4.6780
BibTeX
@article{Mittra2024,
author = {Mittra, Erik S and Wong, Rebecca K S and Winters, Celeste and Brown, Adam and Murley, Shondra and Kennecke, Hagen},
title = {Establishing a robust radioligand therapy program: A practical approach for North American centers},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6780}
}
EUVIMED